Oster H, Mittelman M. Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall. haematol [Internet]. 2026May1 [cited 2026May29];111(5):1523-5. Available from: https://haematologica.org/article/view/13117